BioStock: Phase II results indicate durability of response for Alligator’s CD40 agonist

Report this content

Alligator Bioscience has presented a second round of interim results from a phase II trial with mitazalimab in pancreatic cancer patients. The follow-up evaluation on the first 23 patients shows an objective response rate of 57 per cent – up from 52 per cent at the first evaluation reported in January. The evaluation on the full set of 57 patients reveals an objective response rate of 44 per cent – also susceptible to an increase as the study progresses. More data points indicate that mitazalimab provides a durable response in combination with standard of care chemotherapy. To give us an in-depth analysis, BioStock turned to Alligator’s CMO Sumeet Ambarkhane.

Read the interview with Sumeet Ambarkhane at biostock.se:

https://www.biostock.se/en/2023/06/phase-ii-results-indicate-durability-of-response-for-alligators-cd40-agonist/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Subscribe

Documents & Links

Quick facts

BioStock: Phase II results indicate durability of response for Alligator’s CD40 agonist
Tweet this